Samsung Biologics Union Faces 20 Million Won Penalty for Halting Final Production Stage During Strike

The Incheon District Court's decision on the Samsung Biologics labor dispute highlights a critical tension between workers' rights to strike and the imperative of maintaining essential production lines. While the court acknowledged the union's right to engage in industrial action, its order for a substantial payment of 20 million won per violation if the final manufacturing stages are halted underscores the judiciary's concern for business continuity, particularly in a sensitive sector like biopharmaceuticals.

This ruling, which partially granted the company's request for indirect enforcement, specifies that the union must not instruct its members to stop the final three stages of the manufacturing process, including concentration, buffer exchange, and final product filling. The company had sought a higher penalty of 100 million won per violation, but the court's adjustment suggests a balancing act between protecting corporate interests and not unduly stifling legitimate labor activities.

From the perspective of Samsung Biologics, this is a significant victory. It provides a clear financial deterrent against actions that could cripple its production capabilities, especially during a strike. For the labor union, however, this ruling represents a considerable restriction on their ability to exert pressure during negotiations. The substantial penalty could effectively limit the scope and impact of any future industrial action, raising questions about the true extent of their bargaining power. The court's intervention, while intended to mediate, may be perceived by labor advocates as leaning towards corporate protection, a common concern in labor disputes within South Korea's powerful conglomerates.

“

The labor union shall not instruct its members to stop the final process during the strike period or distribute related guidelines. If violated, 20 million won shall be paid per act.